Over the last 40 years, biotechnology has shaped the landscape of medicine, as evidenced by the fact that 69% of drugs in development are a result of biotechnological advancements.
Read moreLa empresa recibe el premio a la Mejor Trayectoria Viveros CEIN en el Congreso Internacional de Emprendimiento de Alto Impacto
Read moreOryzon Genomics S.A. se complace en compartir que, de acuerdo al ranking publicado por la Unión Europea, se encuentra entre las 1000 empresas europeas con mayor inversión en I+D, en concreto en la p...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read moreCERTERA's objective is to create a coordinated research and innovation structure to accelerate the preclinical and early stage clinical development of these types of therapies.
Read moreThe combined Group, named 3PBIOVIAN, will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for Drug Substance and Drug Pr...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read moreThis new service, offered by the analytical testing service of the clinical research business, ensures biopharmaceutical products are free of contaminants, helping customers deliver safe medicines for...
Read moreIt has been has developed a computational simulation methodology to assess the risk of different drugs inducing cardiac arrhythmias, specifically Torsade de Pointes, as a side effect.
Read moreThe key project objective is to apply state-of-the-art methodologies to prospect the bioactivity potential of lignin – a natural, abundant and sustainable biopolymer component of lignocellulosic bio...
Read moreIn an international study, they propose optimizing the design of clinical trials in rare tumors to speed up the study and approval of new drugs that will make it possible to respond to patients with t...
Read moreEl medicamento biológico basado en microbiota intestinal MBK-01 trata a pacientes infectados con Clostridioides difficile, enfermedad que causa episodios muy graves de diarrea y que puede ser motivo ...
Read more